Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 1;110(10):2475-2480.
doi: 10.3324/haematol.2024.286807. Epub 2025 Feb 6.

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)

Sarah Bertoli  1 , Emilie Bérard  2 , Pierre Peterlin  3 , Romain Guieze  4 , Yohan Desbrosses  5 , Yosr Hicheri  6 , Omar Benbrahim  7 , Martin Carre  8 , Corentin Orvain  9 , Anne Banos  10 , Marc Bernard  11 , Emmanuel Gyan  12 , Alain Saad  13 , Safia Chebrek  14 , Gabrielle Roth Guepin  15 , Veronique Dorvaux  16 , Laurence Sanhes  17 , Maria Pilar Gallego-Hernanz  18 , Carole Exbrayat  19 , Laure Vincent  20 , Chantal Himberlin  21 , Célestine Simand  22 , Norbert Vey  6 , Cindy Fenoll  23 , Ariane Mineur  23 , Anne Huynh  1 , Francois Vergez  24 , Isabelle Luquet  24 , Laetitia Largeaud  24 , Eric Delabesse  24 , Arnaud Pigneux  25 , Christian Récher  26
Affiliations

Dexamethasone added to induction and post-remission therapy in older patients with newly diagnosed acute myeloid leukemia: a multicenter, phase II trial (DEXAML-02)

Sarah Bertoli et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Event-free survival, relapse-free survival and overall survival. (A) Event-free survival in the whole population. (B) Event-free survival according to the 2022 European LeukemiaNet (ELN) classification. (C) Relapse-free survival in the whole population. (D) Relapse-free survival according to the 2022 ELN classification. (E) Overall survival in the whole population. (F) Overall survival according to the 2022 ELN classification. N: number.
See this image and copyright information in PMC

References

    1. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. - PubMed
    1. Castaigne S, Pautas C, Terré C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516. - PubMed
    1. Lancet JE, Uy GL, Newell LF, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8(7):e481-e491. - PubMed
    1. Pigneux A, Béné MC, Salmi LR, et al. Improved survival by adding lomustine to conventional chemotherapy for elderly patients with AML without unfavorable cytogenetics: results of the LAM-SA 2007 FILO trial. J Clin Oncol. 2018;36(32):3203-3210. - PubMed
    1. Bertoli S, Picard M, Bérard E, et al. Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 2018;103(6):988-998. - PMC - PubMed

LinkOut - more resources